CJC-1295 (No DAC) Research Guide
What Is CJC-1295 (No DAC)?
CJC-1295 (No DAC), sometimes referred to as Modified GRF 1-29, is a synthetic peptide analogue of Growth Hormone Releasing Hormone (GHRH). It was developed to mimic the activity of naturally occurring GHRH while incorporating structural modifications designed to improve stability.
Within peptide research, CJC-1295 (No DAC) has become one of the most widely studied GHRH analogues. Researchers are interested in its interaction with growth hormone releasing hormone receptors and its role within endocrine signalling pathways.
Due to its extensive history within scientific literature, CJC-1295 (No DAC) remains one of the most recognised compounds within growth hormone-related peptide research.
Understanding How CJC-1295 (No DAC) Works
CJC-1295 (No DAC) functions as a Growth Hormone Releasing Hormone (GHRH) analogue.
Researchers have investigated how GHRH analogues interact with receptors located within the anterior pituitary gland, influencing signalling pathways involved in endogenous growth hormone release.
The structural modifications present within CJC-1295 (No DAC) were developed to increase resistance to enzymatic degradation while maintaining its interaction with GHRH receptors.
As a result, it is often studied alongside other compounds involved in growth hormone signalling research.
Why Researchers Study CJC-1295 (No DAC)
CJC-1295 (No DAC) has been investigated across several scientific disciplines, including:
- Endocrine signalling
- Growth hormone regulation
- Hormone-receptor interactions
- Cellular signalling pathways
- Metabolic research
- Healthy ageing research
- Peptide engineering
Its well-documented mechanism and extensive research history continue to make it a significant subject of scientific investigation.
What Does "No DAC" Mean?
One of the most common questions surrounding CJC-1295 is the meaning of "No DAC."
DAC stands for Drug Affinity Complex, a modification designed to extend the duration of activity of certain peptide compounds.
CJC-1295 (No DAC) does not contain this modification. Instead, it is commonly referred to as Modified GRF 1-29 and represents a separate variant from CJC-1295 with DAC.
Although both compounds belong to the GHRH analogue family, they differ structurally and are often studied independently.
CJC-1295 (No DAC) vs CJC-1295 with DAC
While the names are similar, these are distinct compounds.
CJC-1295 (No DAC)
A modified GHRH analogue without a Drug Affinity Complex (DAC).
CJC-1295 with DAC
A modified GHRH analogue incorporating a Drug Affinity Complex designed to prolong activity.
Both compounds are commonly studied within growth hormone signalling research but differ in structure and pharmacokinetic characteristics.
CJC-1295 (No DAC) Compared to Other Research Peptides
CJC-1295 (No DAC)
A synthetic GHRH analogue commonly referred to as Modified GRF 1-29.
Tesamorelin
A synthetic GHRH analogue with a distinct structure and development history.
Ipamorelin
A Growth Hormone Releasing Peptide (GHRP) that acts through the ghrelin receptor pathway rather than the GHRH receptor pathway.
CJC-1295 & Ipamorelin
A combination frequently investigated due to the involvement of multiple signalling pathways associated with growth hormone release.
Each compound possesses a unique structure and may be studied for different research purposes.
Product Specifications
Compound: CJC-1295 (No DAC)
Alternative Name: Modified GRF 1-29
Quantity: 5mg
Form: Lyophilised powder
Appearance: White to off-white powder
Storage: Store refrigerated upon receipt
Testing: Independently batch tested
Research Classification: GHRH Analogue
Independent Batch Testing
At Platinum Peptides, transparency and quality assurance remain central to our approach.
Every batch undergoes independent third-party analytical testing to verify identity and purity before being released.
Why Batch Testing Matters
Identity Verification
Confirms that the material matches the labelled compound.
Purity Analysis
Provides confidence that the sample meets established quality standards.
Consistency
Helps ensure batch-to-batch reliability and reproducibility.
Transparency
Allows researchers to review independent analytical data before making purchasing decisions.
Certificates of Analysis are available for each batch where applicable.
Storage Information
Lyophilised peptides should be stored in a cool, dry environment and protected from excessive heat, moisture and direct sunlight.
Researchers should always review appropriate storage conditions relevant to their specific protocols and applications.
Frequently Asked Questions
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a synthetic Growth Hormone Releasing Hormone (GHRH) analogue commonly studied within endocrine and peptide research.
Is CJC-1295 (No DAC) the same as Modified GRF 1-29?
Yes. CJC-1295 (No DAC) is often referred to as Modified GRF 1-29.
What does DAC stand for?
DAC stands for Drug Affinity Complex, a modification used to extend the duration of activity of certain peptide compounds.
Is CJC-1295 (No DAC) the same as CJC-1295 with DAC?
No. Although closely related, they are distinct compounds with different structures.
What type of peptide is CJC-1295 (No DAC)?
It is classified as a Growth Hormone Releasing Hormone (GHRH) analogue.
Is CJC-1295 (No DAC) batch tested?
Yes. Platinum Peptides uses independent third-party testing to verify batch quality and purity.
How should CJC-1295 (No DAC) be stored?
Store in accordance with established peptide storage guidelines and maintain refrigeration where appropriate.
Related Research Compounds
Researchers interested in CJC-1295 (No DAC) may also wish to explore:
Important Information
This product is supplied strictly for laboratory research purposes only.
It is not intended for human consumption, therapeutic use, diagnostic use or veterinary use.
Researchers are responsible for ensuring compliance with all applicable laws, regulations and research protocols relating to the handling and use of peptide compounds.